Anaerobe 2016: 13th Biennial Congress of the Anaerobe Society of the Americas
Options IX for the Control of Influenza
21st Annual Infectious Disease Board Review Course
17th Internatinal Symposium on Staphylococci and Staphylococcal Infections (ISSSI)
Find Practice Guidelines
IDSA Zika Vote Statement (PDF)
IDSA urges Congress to pass the strongest emergency bill possible to combat Zika and to reject efforts to fund the Zika response at the expense of equally critical health funding.
IDSA, ASM, and PASCV Letter to FDA on LDTs (PDF)
IDSA, ASM and the Pan-American Society for Clinical Virology urge FDA to consider the vital role of lab developed tests in rapidly diagnosing and appropriately treating infectious diseases.
PACCARB Press Release
Recommendations from the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria reflect IDSA input.
IDSA & HIVMA Engage HHS on Drug Pricing and Innovation
IDSA and HIVMA wrote to HHS Secretary Burwell to distinguish efforts to incentivize development of desperately needed new drugs from recent actions to significantly increase the costs of decades old drugs.
IDSA Writes to Senate Aging Committee Ahead of Hearing on Drug Pricing Spikes
IDSA wrote to the Senate Special Committee on Aging ahead of a planned hearing on recent drug price spikes. The IDSA letter distinguished efforts to incentivize development of desperately needed new drugs from recent actions to significantly increase the costs of decades old drugs.
IDSA Leads Stakeholders In Support of R&D Tax Credit for Antibiotics and Rapid Diagnostics
Forty groups representing providers, patients, public health and industry joined a letter – circulated by IDSA – supporting the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act, H.R. 3539.
IDSA Statement: White House Antibiotic Stewardship Forum
At this week’s White House Forum on Stewardship, IDSA President Steve Calderwood, MD, FIDSA said, “Our expertise on diagnosing and treating patients with serious infectious diseases makes us particularly well suited to lead multi-disciplinary institution-level stewardship programs that will improve patient outcomes”
Senators Urged to Support Antibiotic R&D Bill
A bill to establish a new FDA approval pathway for antibacterial drugs to treat life-threatening infections where there exists an unmet medical need has been introduced in the Senate. IDSA members asked to engage their Senators.
1 of 8
Possible Zika Virus Infection Among Pregnant Women — United States and Territories, May 2016
May 20, 2016 - In February 2016, CDC, in collaboration with state, local, tribal, and territorial health departments, launched comprehensive surveillance systems to report and actively monitor pregnancies and congenital outcomes among symptomatic and asymptomatic women with laboratory evidence of possible Zika virus infection.
Nizoral ketoconazole Oral Tablets: Prescribing for Unapproved Uses including Skin and Nail Infections Continues; Linked to Patient Death
Fluoroquinolone Antibacterial Drugs: Drug Safety Communication - FDA Advises Restricting Use for Certain Uncomplicated Infections
Interim Guidance for Zika Virus Testing on Urine
May 10, 2016 - CDC updated its interim diagnostic testing guidance for Zika virus in public health laboratories based on preliminary data demonstrating that Zika virus can be found at higher levels or for longer duration in urine than in serum (blood)
FDA Evaluating Study Examining Use of Oral Fluconazole (Diflucan) in Pregnancy
CDC and OSHA Issue Interim Guidance for Protecting Workers from Occupational Exposure to Zika Virus
CDC concludes Zika causes microcephaly and other birth defects
April 14, 2016 - Scientists at the Centers for Disease Control and Prevention (CDC) have concluded, after careful review of existing evidence, that Zika virus is a cause of microcephaly and other severe fetal brain defects.
Focus Diagnostics Laboratory Examination Kits: Class I Recall - Inaccurate Test Results
>> Read More
Acute infection screening programs, which can detect HIV earlier, may lead to lower rates of transmission, a new CID study suggests.
From the PresidentIDSA and SHEA Release New Guideline on Antibiotic StewardshipIDSA Adopts All-In Match PolicyIDWeek Mentorship ProgramJournal Club
The Society’s next top staffer brings extensive experience in association management and has a track record for organizational leadership representing healthcare professionals.
The new IDSA guidelines on Implementing an Antimicrobial Stewardship Program focus on specific strategies that the evidence suggests are most beneficial to ensure the program will be effective and sustainable.
A new study in CID suggests seasonal flu vaccination during pregnancy may guard against stillbirth.
From the PresidentIDWeek 2016Call for Committee VolunteersPresident's Budget RequestJournal Club
The latest release of the guidance reflects several important developments, including the recent approval of the second single-tablet fixed dose combination regimen (elbasvir/grazoprevir) for the treatment of HCV.
1 of 7
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2016 Infectious Diseases Society of America